Change in the number of votes relating to Biotie Therapies Corp.'s shares

Biotie Therapies Corp.          Stock Exchange Release    5 July 2011 at 10.00
a.m.
 
Change in the number of votes relating to Biotie Therapies Corp.'s shares
 
The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"),
Biotie Therapies Holding AG (previously Synosia Therapeutics Holding AG) has
conveyed 899,071 of Biotie shares (together with the changes announced in June,
2011 a total of 3,031,931 Biotie shares) against consideration pursuant to the
option programs.
 
The conveyed shares previously held by the Company's subsidiary have not carried
any voting rights. As a result of the conveyances, the total number of votes
attached to Biotie's shares increased by 899,071 votes to 375,714,233 votes. The
conveyance does not affect the number of registered shares (total of
387,594,457 shares) but the number of the Company's shares held by the Biotie
Therapies group is reduced to 11,880,224 shares. The parent company Biotie does
not own any treasury shares.
 
The conveyance of Biotie shares relates to the option plan of Synosia
Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia")
acquired by Biotie in February 2011. According to such Synosia share option
plan, options have been granted to employees, former directors and consultants.
In connection with the completion of the acquisition of Synosia, the option plan
was amended so that instead of shares in Synosia an aggregate maximum of
14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued
these 14,912,155 shares to its current subsidiary Synosia in connection with the
acquisition to be further conveyed to the option holders when they potentially
exercise their option rights in accordance with the terms and conditions of the
option program.
 
After these conveyances, the total number of shares which can be subscribed by
virtue of the Synosia option plans amounts to 11,880,224 which represents 3.1%
of the total amount of shares in the Company.
 
Turku, 5 July 2011
 
Biotie Therapies Corp.
 
Timo Veromaa
President and CEO
 
For further information, please contact:
 
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com
 
DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: Biotie Therapies Oyj via Thomson Reuters ONE
 
[HUG#1528360]